Compare ARKO & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARKO | SENS |
|---|---|---|
| Founded | 1970 | 1996 |
| Country | United States | United States |
| Employees | 9748 | N/A |
| Industry | Oil Refining/Marketing | Industrial Machinery/Components |
| Sector | Energy | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 466.7M | 476.9M |
| IPO Year | 2021 | 2014 |
| Metric | ARKO | SENS |
|---|---|---|
| Price | $4.13 | $8.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $8.50 | ★ $13.67 |
| AVG Volume (30 Days) | ★ 712.6K | 670.0K |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.88% | N/A |
| EPS Growth | ★ 15.38 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,142,799,000.00 | $16,389,000.00 |
| Revenue This Year | $22.11 | $82.21 |
| Revenue Next Year | N/A | $55.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 23.26 | 19.85 |
| 52 Week Low | $3.94 | $0.41 |
| 52 Week High | $8.76 | $10.64 |
| Indicator | ARKO | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 38.77 | 45.48 |
| Support Level | $3.98 | $8.45 |
| Resistance Level | $4.96 | $10.07 |
| Average True Range (ATR) | 0.15 | 0.47 |
| MACD | 0.04 | -0.18 |
| Stochastic Oscillator | 40.85 | 16.13 |
ARKO Corp owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in four segments: Retail segment, Wholesale segment, fleet fueling segment, and GPM Petroleum segment. It derives the majority of its revenue from retail and wholesale distribution of fuel.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.